A Phase 1 interventional study of NW-3509a in Schizophrenia, sponsored by Newron Pharmaceuticals SPA. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-20.
Sponsored by Newron Pharmaceuticals SPA · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 754th largest by enrollment of the 1,319 interventional ones that give a count, is one of 68 that started in 2013, is one of 196 in phase 1, and was the 773rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,465 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 68 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,319 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,465 have an industry lead sponsor. The 10 most frequent:
Newron Pharmaceuticals SPA is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
Newron Pharmaceuticals SPA has 4 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,465 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, 8-day, randomized, double-blind, placebo-controlled, sequential-cohort study designed to evaluate the safety, tolerability, and MTD of single escalating oral doses of NW-3509A in healthy male volunteers. Six independent cohorts of 12 volunteers each will participate in this study, with the first 9 volunteers in each cohort to qualify being randomized to receive study medication and the remaining 3 to be used as backups/ alternates. In each cohort, 6 subjects will be randomly assigned to receive NW-3509A and 3 subjects will receive placebo.
Doses from 1 to 30 mg were tested
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Volunteers will meet the following demographic inclusion criteria:
The subject has a body weight of at least 45 kg and a of ≤30.
Procedural
Volunteers will meet the following procedural criteria:
Exclusion Criteria:
The presence of any of the following will exclude a subject from study enrollment:
General Medical Status
A current diagnosis of acute, severe, or unstable asthmatic condition.
Cardiovascular
Vital signs (supine) outside the following ranges:
CNS related
History or current diagnosis of epilepsy or seizure disorder.
Psychiatric
Subjects with current or past suicidal ideation.
Study-specific criteria
Smoker; currently or at any time in the last 5 years;
Laboratory abnormalities
Clinically important laboratory abnormalities in thyroid function tests at screening:
Concomitant therapy
Ingested any of the following substances:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NW-3509a - 1mg or placebo
Drug: NW-3509a
NW-3509a 2mg or placebo
Drug: NW-3509a
NW-3509a 5mg or placebo
Drug: NW-3509a
NW-3509a 10 mg or placebo
Drug: NW-3509a
NW-3509a 20 mg or placebo
Drug: NW-3509a
NW-3509a 30 mg or placebo
Drug: NW-3509a
single dose
Also known as: NW-3509
Physical Examination Shift Table
Physical examinations were carried out on the following: Lymph nodes, mouth, neck, nervous system, nose, skin and throat.
Time frame: Day -1(pre-dose) through Day 8 (Discharge)
Maximum Plasma Concentration of NW-3509A at Doses Tested
Plasma concentration data, derived PK parameters, and urine data are summarized as maximum plasma concentration (Cmax). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).
Time frame: Baseline up to 32 hours post-dose
Total Drug Exposure Over Time (AUC0-t) of NW-3509A at Doses Tested
Plasma concentration data, derived PK parameters, and urine data were summarized as total drug exposure over time (AUC0-t). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).
Time frame: Baseline up to 32 hours post-dose
A total of 54 healthy males, who were between the age of 18-45 years old, with a minimum body weight of 45 kg and body mass index of more than or equal to 30, were recruited and observed in the period from 23rd of July 2013 till 19th of September 2014 in this study conducted at a single site in the US.
| Milestone | Placebo | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|---|
| Started | 18 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 18 | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Physical examinations were carried out on the following: Lymph nodes, mouth, neck, nervous system, nose, skin and throat.
| Participants abnormal at end of study | Placebo | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|---|
| Physical Examination Shift Table | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
Plasma concentration data, derived PK parameters, and urine data are summarized as maximum plasma concentration (Cmax). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).
| ng/mL | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Maximum Plasma Concentration of NW-3509A at Doses Tested | 2.08 ± 1.20 | 3.49 ± 1.98 | 14.2 ± 7.2 | 22.5 ± 16.4 | 36.4 ± 30.1 | 93.3 ± 18.0 |
Plasma concentration data, derived PK parameters, and urine data were summarized as total drug exposure over time (AUC0-t). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).
| ng.h/mL | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Total Drug Exposure Over Time (AUC0-t) of NW-3509A at Doses Tested | 6.71 ± 9.24 | 13.4 ± 11.2 | 56.7 ± 30.5 | 101 ± 86 | 166 ± 175 | 350 ± 34 |
Collected over Adverse Event evaluations were performed during the screening period, at baseline, Day 2 and Day 8. In addition, all subjects were followed up for 30 days after their dose of study medication for the occurrence of any SAEs. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/18 (0%) | 6/18 (33.3%) |
| Cohort 1 | — | 0/6 (0%) | 3/6 (50%) |
| Cohort 2 | — | 0/6 (0%) | 1/6 (16.7%) |
| Cohort 3 | — | 0/6 (0%) | 3/6 (50%) |
| Cohort 4 | — | 0/6 (0%) | 2/6 (33.3%) |
| Cohort 5 | — | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 6 | — | 0/6 (0%) | 3/6 (50%) |
| Event | Placebo | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|---|
| Postural Orthostatic and tachycardia syndromeCardiac disorders | 0/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 |
| ConfusionInjury, poisoning and procedural complications | 1/18 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 |
| ConstipationGastrointestinal disorders | 1/18 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| NauseaGastrointestinal disorders | 0/18 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| Feeling hotGeneral disorders | 0/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/18 | 1/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| ExcoriationSkin and subcutaneous tissue disorders | 0/18 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Thermal burnSkin and subcutaneous tissue disorders | 0/18 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Blood creatine phosphate kinaseInvestigations | 0/18 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/18 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
9 healthy volunteers were assigned per cohort, within which 6 subjects received NW-3509A and 3 subjects received placebo by randomised selection.
| Age, Customized(years) | Placebo | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|---|
| 18-45 | 31.27 ± 7.71 | 28.33 ± 6.31 | 23.83 ± 6.91 | 30.33 ± 8.12 | 34.83 ± 5.85 | 29.50 ± 3.51 | 24.33 ± 3.56 | 28.92 ± 3.88 |
| Sex: Female, Male(Participants) | Placebo | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 18 | 6 | 6 | 6 | 6 | 6 | 6 | 54 |
| Race/Ethnicity, Customized(participants) | Placebo | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 1 | 2 | 2 | 0 | 8 |
| African American | 7 | 2 | 4 | 4 | 3 | 4 | 1 | 25 |
| Asian | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 5 |
| Caucasian | 8 | 2 | 1 | 1 | 0 | 0 | 3 | 15 |
| Native American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Placebo | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 18 | 6 | 6 | 6 | 6 | 6 | 6 | 54 |
The record gives a start of Jun 2013, a primary completion of Sep 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.